[go: up one dir, main page]

BRPI0921701B8 - Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende - Google Patents

Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende

Info

Publication number
BRPI0921701B8
BRPI0921701B8 BRPI0921701A BRPI0921701A BRPI0921701B8 BR PI0921701 B8 BRPI0921701 B8 BR PI0921701B8 BR PI0921701 A BRPI0921701 A BR PI0921701A BR PI0921701 A BRPI0921701 A BR PI0921701A BR PI0921701 B8 BRPI0921701 B8 BR PI0921701B8
Authority
BR
Brazil
Prior art keywords
compound
single bond
pharmaceutical composition
catechol group
optionally substituted
Prior art date
Application number
BRPI0921701A
Other languages
English (en)
Inventor
Yamawaki Kenji
Takeoka Yusuke
Sugimoto Hideki
Hisakawa Shinya
Aoki Toshiaki
Nishitani Yasuhiro
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42128829&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0921701(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BRPI0921701A2 publication Critical patent/BRPI0921701A2/pt
Publication of BRPI0921701B1 publication Critical patent/BRPI0921701B1/pt
Publication of BRPI0921701B8 publication Critical patent/BRPI0921701B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D501/00—Heterocyclic compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D501/14—Compounds having a nitrogen atom directly attached in position 7
    • C07D501/16—Compounds having a nitrogen atom directly attached in position 7 with a double bond between positions 2 and 3
    • C07D501/20—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids
    • C07D501/24—7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with hydrocarbon radicals, substituted by hetero atoms or hetero rings, attached in position 3
    • C07D501/38—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof
    • C07D501/46—Methylene radicals, substituted by nitrogen atoms; Lactams thereof with the 2-carboxyl group; Methylene radicals substituted by nitrogen-containing hetero rings attached by the ring nitrogen atom; Quaternary compounds thereof with the 7-amino radical acylated by carboxylic acids containing hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D505/00—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D505/10—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D505/12—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7
    • C07D505/14—Heterocyclic compounds containing 5-oxa-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. oxacephalosporins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 substituted in position 7 with hetero atoms directly attached in position 7
    • C07D505/16—Nitrogen atoms
    • C07D505/18—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof
    • C07D505/20—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D505/24—Nitrogen atoms further acylated by radicals derived from carboxylic acids or by nitrogen or sulfur analogues thereof with the acylating radicals further substituted by hetero atoms or by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen further substituted by doubly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C07D519/06—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00 containing at least one condensed beta-lactam ring system, provided for by groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00, e.g. a penem or a cepham system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

composto cefalosporinas tendo um grupo catecol, uso do mesmo e composição farmacêutica compreendendo o dito composto. a presente invenção refere-se a compostos cefem que têm um amplo espectro antimicrobiano e têm potente atividade antimicrobiana contra bactérias gram-negativas produtoras de beta-lactamase, como segue: um composto da fórmula: fórmula 1 (i) em que, x é n, ch ou c-ci; t é s ou similares; a e g são alquileno inferior ou similar; b é uma ligação simples ou similar; d é uma ligação simples, nr7-, co-, co-nr7-, nr7-co-, -nr7 -co-nr7-, ou similares; e é alquileno inferior opcionalmente substituído; f é uma ligação simples ou fenileno opcionalmente substituído; r3, r4, r5 e r6 são, cada um independentemente, hidrogênio, halogênio, nitrila, ou similares; ou um éster, um composto protegido no amino do anel na cadeia lateral 7, um sal farmaceuticamente aceitável, ou um solvato do mesmo.
BRPI0921701A 2008-10-31 2009-10-27 Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende BRPI0921701B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2008-280828 2008-10-31
JP2008280828 2008-10-31
PCT/JP2009/068400 WO2010050468A1 (ja) 2008-10-31 2009-10-27 カテコール基を有するセファロスポリン類

Publications (3)

Publication Number Publication Date
BRPI0921701A2 BRPI0921701A2 (pt) 2020-08-11
BRPI0921701B1 BRPI0921701B1 (pt) 2022-05-03
BRPI0921701B8 true BRPI0921701B8 (pt) 2022-11-29

Family

ID=42128829

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921701A BRPI0921701B8 (pt) 2008-10-31 2009-10-27 Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende

Country Status (38)

Country Link
US (1) US9238657B2 (pt)
EP (2) EP2341053B1 (pt)
JP (2) JP5498393B2 (pt)
KR (1) KR101655961B1 (pt)
CN (1) CN102203100B (pt)
AU (1) AU2009310959B2 (pt)
BR (1) BRPI0921701B8 (pt)
CA (1) CA2736953C (pt)
CL (1) CL2011000939A1 (pt)
CO (1) CO6331443A2 (pt)
CR (1) CR20110144A (pt)
CY (2) CY1118536T1 (pt)
DK (1) DK2960244T3 (pt)
EA (1) EA019520B1 (pt)
ES (2) ES2564836T3 (pt)
FI (1) FIC20200039I1 (pt)
FR (1) FR20C1050I2 (pt)
HR (1) HRP20161408T1 (pt)
HU (2) HUE031802T2 (pt)
IL (1) IL211720A (pt)
LT (2) LT2960244T (pt)
MA (1) MA32731B1 (pt)
ME (1) ME02666B (pt)
MX (1) MX2011004636A (pt)
MY (1) MY155655A (pt)
NL (1) NL301067I2 (pt)
NO (1) NO2020035I1 (pt)
NZ (1) NZ591728A (pt)
PE (1) PE20120010A1 (pt)
PL (1) PL2960244T3 (pt)
PT (1) PT2960244T (pt)
RS (1) RS55365B1 (pt)
SI (1) SI2960244T1 (pt)
SM (1) SMT201600397B (pt)
TW (1) TWI535727B (pt)
UA (1) UA105190C2 (pt)
WO (1) WO2010050468A1 (pt)
ZA (1) ZA201102024B (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2209474A4 (en) 2007-10-09 2013-07-24 Sopharmia Inc BROAD SPECTRUM BETA-LACTAMASE INHIBITORS
PT2960244T (pt) * 2008-10-31 2016-11-02 Shionogi & Co Cefalosporina contendo grupo catecol
CN102918047A (zh) 2010-04-05 2013-02-06 盐野义制药株式会社 具有假儿茶酚基团的头孢烯类化合物
US9145425B2 (en) * 2010-04-05 2015-09-29 Shionogi & Co., Ltd. Cephem compound having catechol group
US9085589B2 (en) 2010-04-28 2015-07-21 Shionogi & Co., Ltd. Cephem derivative
EP2966061B1 (en) * 2011-03-04 2017-05-03 Life Technologies Corporation Compounds and methods for conjugation of biomolecules
KR101719556B1 (ko) * 2011-03-30 2017-03-24 주식회사 레고켐 바이오사이언스 신규한 세파로스포린 유도체 및 이를 함유하는 의약 조성물
KR20140039202A (ko) 2011-04-28 2014-04-01 시오노기세야쿠 가부시키가이샤 카테콜 또는 의사 카테콜 구조를 갖는 신규 세펨 화합물
JPWO2013002215A1 (ja) 2011-06-27 2015-02-23 塩野義製薬株式会社 ピリジニウム基を有するセフェム化合物
TWI547496B (zh) * 2011-10-04 2016-09-01 葛蘭素集團公司 抗菌化合物
WO2013051597A1 (ja) 2011-10-04 2013-04-11 塩野義製薬株式会社 カテコール基を有するセフェム誘導体
UY35103A (es) * 2012-10-29 2014-05-30 Glaxo Group Ltd Compuestos de cefem 2-sustituidos
BR112015008905A2 (pt) 2012-10-29 2017-07-04 Shionogi & Co processos para a produção de intermediários de compostos de 2-alquil cefem
JPWO2014104148A1 (ja) * 2012-12-26 2017-01-12 塩野義製薬株式会社 セフェム化合物
EP3043797B1 (en) 2013-09-09 2020-04-08 Merck Sharp & Dohme Corp. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
JP6153674B2 (ja) 2014-03-24 2017-06-28 ノバルティス アーゲー 細菌感染を治療するためのモノバクタム有機化合物
JP6377570B2 (ja) * 2014-04-28 2018-08-22 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ ２−置換セフェム化合物を含有する医薬組成物
HRP20210693T1 (hr) 2014-06-11 2021-06-11 VenatoRx Pharmaceuticals, Inc. Inhibitori beta-laktamaze
EP3189841B1 (en) * 2014-09-04 2023-11-22 Shionogi & Co., Ltd. Pharmaceutical preparation comprising cephalosporin having catechol groups
HUE056038T2 (hu) * 2014-09-04 2022-01-28 Shionogi & Co Cefalosporin-származék sója, annak kristályos szilárd alakja és eljárás annak elõállítására
CN106661052B (zh) * 2014-09-04 2021-05-11 盐野义制药株式会社 头孢菌素衍生物的中间体及其制造方法
JP2018521021A (ja) 2015-06-11 2018-08-02 バジリア・ファルマスーチカ・インターナショナル・アーゲーＢａｓｉｌｅａ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｉｎｔｅｒｎａｔｉｏｎａｌ Ａｇ 排出ポンプ阻害剤及びその治療的使用
JP6837480B2 (ja) 2015-09-23 2021-03-03 ノバルティス アーゲー モノバクタム抗生物質の塩および固体形態
WO2017096472A1 (en) 2015-12-10 2017-06-15 Naeja-Rgm Pharmaceuticals Inc. Cephem compounds, their production and use
US10858366B2 (en) 2016-03-08 2020-12-08 Novartis Ag Tricyclic compounds useful to treat orthomyxovirus infections
WO2017216765A1 (en) * 2016-06-17 2017-12-21 Wockhardt Limited Antibacterial compositions
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
KR102694317B1 (ko) * 2017-06-09 2024-08-09 포브 신서시스 인코포레이티드 세균 감염의 치료를 위한 카바페넴 화합물 및 조성물
JP7235718B2 (ja) * 2017-08-02 2023-03-08 ノバルティス アーゲー モノバクタム系抗生物質およびその中間体を製造するための化学的方法
CR20200372A (es) 2018-02-28 2020-10-26 Novartis Ag Derivados de 10-(di(fenil)metil)-4-hidroxi8,9,9a,10-tetrahidro-7h-pirrolo (1`, 2`:4-5) pirazino (1,2-b) piridazina-3, 5-diona y compuestos relacionados como inhibidores de la replicación del ortomixo virus para el tratamiento de la influenza
EP3802551A4 (en) 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2020184399A1 (ja) * 2019-03-08 2020-09-17 塩野義製薬株式会社 抗菌用医薬組成物
WO2021043973A1 (en) * 2019-09-06 2021-03-11 Nabriva Therapeutics GmbH Siderophore cephalosporin conjugates and uses thereof
WO2021147986A1 (zh) * 2020-01-22 2021-07-29 上海森辉医药有限公司 头孢类抗菌化合物及其在医药上的应用
TW202220663A (zh) 2020-07-28 2022-06-01 日商鹽野義製藥股份有限公司 含有具有鄰苯二酚基之頭孢菌素類的凍結乾燥製劑及其製造方法
CA3204655A1 (en) * 2021-01-12 2022-07-21 Jian Huang Cephalosporin antibacterial compound and preparation method therefor
CN113698365A (zh) * 2021-08-30 2021-11-26 成都大学 一种头孢地尔侧链的制备方法
WO2024245383A1 (zh) * 2023-06-01 2024-12-05 江苏恒瑞医药股份有限公司 一种包含头孢类抗菌化合物的药物组合物
CN117024377B (zh) * 2023-08-15 2025-04-29 济南大学 一种2-氯-3,4-二对甲氧苯甲氧基-n-(2-(1-吡咯烷)乙基)苯甲酰胺的制备方法
CN117069638A (zh) * 2023-08-17 2023-11-17 济南大学 一种头孢地尔中间体的制备方法
CN117088764B (zh) * 2023-08-24 2026-01-30 济南大学 一种头孢地尔关键中间体的合成和后处理方法
US12225906B1 (en) 2024-09-26 2025-02-18 Terry Earl Brady Pathogenic affinity pathway of infectious or parasitic organisms for nanogram and picogram dosimetry prophylaxis or cure

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47168A (en) 1974-05-09 1979-07-25 Toyama Chemical Co Ltd Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same
JPS57118588A (en) 1981-11-26 1982-07-23 Toyama Chem Co Ltd Novel cephalosporin
DE3207840A1 (de) 1982-03-04 1983-09-15 Hoechst Ag, 6230 Frankfurt "cephalosporinderivate und verfahren zu ihrer herstellung"
DE3470314D1 (en) 1983-01-21 1988-05-11 Beecham Group Plc Beta-lactam antibacterial agents
NO165842C (no) 1984-04-23 1991-04-17 Takeda Chemical Industries Ltd Analogifremgangsmaate for fremstilling av terapeutisk aktive cefem-forbindelser.
EP0168177A3 (en) 1984-06-28 1987-04-01 Pfizer Limited Cephalosporin antibiotics
EP0203271B1 (en) 1985-03-01 1993-05-26 Takeda Chemical Industries, Ltd. Antibacterial compounds, their production and use
JPH068300B2 (ja) * 1985-08-02 1994-02-02 萬有製薬株式会社 新規セフアロスポリン誘導体
EP0211656A3 (en) 1985-08-10 1988-03-09 Beecham Group Plc Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them
CA1299564C (en) * 1985-09-03 1992-04-28 Akihiro Shimabayashi Cephalosporin derivative
JPH07107069B2 (ja) * 1985-09-03 1995-11-15 大塚化学株式会社 セフアロスポリン化合物の新規誘導体、その製造法及び該誘導体を含有する医薬組成物
JPS62158291A (ja) * 1986-01-07 1987-07-14 Sagami Chem Res Center セフアロスポリン誘導体
DE3750411T2 (de) 1986-04-14 1995-03-16 Banyu Pharma Co Ltd Cephalosporinderivate, Verfahren zu ihrer Herstellung und antibakterielle Präparate.
EP0346465B1 (en) 1986-04-14 1993-08-11 Banyu Pharmaceutical Co., Ltd. 1-carboxy-1-vyniloxyiminoaminothiazole cephalosporing derivatives and process for their preparation
IE61679B1 (en) 1987-08-10 1994-11-16 Fujisawa Pharmaceutical Co Water-soluble antibiotic composition and water-soluble salts of new cephem compounds
GB8719875D0 (en) 1987-08-22 1987-09-30 Beecham Group Plc Compounds
JPH0228185A (ja) * 1988-04-14 1990-01-30 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその合成中間体
US5149803A (en) * 1988-05-10 1992-09-22 Imperial Chemical Industries Plc Intermediates for cephalosporin compounds
GB8811055D0 (en) 1988-05-10 1988-06-15 Ici Plc Antibiotic compounds
PH25965A (en) * 1988-06-06 1992-01-13 Fujisawa Pharmaceutical Co New cephem compounds which have antimicrobial activities
US5244890A (en) 1988-06-06 1993-09-14 Fujisawa Pharmaceutical Co., Ltd. Cephem compounds
GB8813945D0 (en) 1988-06-13 1988-07-20 Fujisawa Pharmaceutical Co New cephem compounds & process for preparation thereof
GB8817653D0 (en) 1988-07-25 1988-09-01 Fujisawa Pharmaceutical Co New cephem compounds & processes for preparation thereof
CA2005787A1 (en) 1988-12-29 1990-06-29 Masao Wada Cephalosporin compounds
JPH02275886A (ja) 1988-12-29 1990-11-09 Tanabe Seiyaku Co Ltd セファロスポリン化合物及びその製法
US5143910A (en) * 1989-09-07 1992-09-01 Shionogi & Co., Ltd. Piperaziniocephalosporins
GB9005246D0 (en) 1990-03-08 1990-05-02 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
US5095012A (en) 1990-08-23 1992-03-10 Bristol-Myers Squibb Company Antibiotic c-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5126336A (en) 1990-08-23 1992-06-30 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
US5234920A (en) 1990-08-23 1993-08-10 Bristol-Myers Squibb Company Antibiotic C-7 catechol-substituted cephalosporin compounds, compositions, and method of use thereof
US5194433A (en) 1990-11-13 1993-03-16 Bristol-Myers Squibb Company Antibiotic c-3 catechol-substituted cephalosporin compounds, compositions and method of use thereof
GB9111406D0 (en) 1991-05-28 1991-07-17 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
GB9118672D0 (en) 1991-08-30 1991-10-16 Fujisawa Pharmaceutical Co New cephem compounds and processes for preparation thereof
EP0628562A1 (fr) 1993-06-10 1994-12-14 Roussel Uclaf Céphalosporines comportant en position 7 un radical oxymino substitué, leurs intermédiaires, leurs procédé de préparation et leur application comme médicaments
AU1694099A (en) 1997-12-26 1999-07-19 Cheil Jedang Corporation Cephem derivatives and a method for producing the compounds and an antibacterialcomposition containing the compounds
CA2441790A1 (en) 2001-03-27 2002-10-03 Actelion Pharmaceuticals Ltd. 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists
JP2003078440A (ja) 2001-08-30 2003-03-14 Kyocera Corp 高周波スイッチ回路
TW200305422A (en) 2002-03-18 2003-11-01 Shionogi & Co Broad spectrum cefem compounds
WO2003099826A1 (en) 2002-05-23 2003-12-04 Orchid Chemicals And Pharmaceuticals Limited A new process for the preparation of cefditoren using the thioester of thiazolylacetic acid
JP4892926B2 (ja) 2005-10-25 2012-03-07 宇部興産株式会社 スルホン化芳香族ブロック共重合体の製造方法
JP3928086B2 (ja) 2005-03-29 2007-06-13 塩野義製薬株式会社 ３−プロペニルセフェム誘導体
JP4557859B2 (ja) 2005-09-29 2010-10-06 富士通株式会社 周波数分割多重送受信装置及び送受信方法
WO2007096740A2 (en) 2006-02-20 2007-08-30 Orchid Research Laboratories Limited Novel cephalosporins
JP2009530228A (ja) 2006-03-16 2009-08-27 アステラス製薬株式会社 セフェム化合物および抗菌薬としての利用
PT2960244T (pt) 2008-10-31 2016-11-02 Shionogi & Co Cefalosporina contendo grupo catecol
CN102918047A (zh) 2010-04-05 2013-02-06 盐野义制药株式会社 具有假儿茶酚基团的头孢烯类化合物
US9145425B2 (en) 2010-04-05 2015-09-29 Shionogi & Co., Ltd. Cephem compound having catechol group
US9085589B2 (en) 2010-04-28 2015-07-21 Shionogi & Co., Ltd. Cephem derivative

Also Published As

Publication number Publication date
EP2960244B1 (en) 2016-09-14
IL211720A (en) 2015-01-29
CY2020034I2 (el) 2021-05-05
MA32731B1 (fr) 2011-10-02
TWI535727B (zh) 2016-06-01
LTC2960244I2 (lt) 2023-10-10
NL301067I2 (nl) 2020-10-28
LT2960244T (lt) 2016-11-25
KR20110090982A (ko) 2011-08-10
US20110190254A1 (en) 2011-08-04
NO2020035I1 (no) 2020-10-21
HRP20161408T1 (hr) 2016-12-02
ES2602969T3 (es) 2017-02-23
PL2960244T3 (pl) 2017-03-31
ZA201102024B (en) 2014-08-27
EP2960244A1 (en) 2015-12-30
PT2960244T (pt) 2016-11-02
CR20110144A (es) 2011-09-09
HUS2000042I1 (hu) 2020-11-30
IL211720A0 (en) 2011-06-30
DK2960244T3 (en) 2016-11-28
EP2341053A1 (en) 2011-07-06
CA2736953A1 (en) 2010-05-06
CN102203100A (zh) 2011-09-28
MX2011004636A (es) 2011-06-20
EP2341053B1 (en) 2016-01-13
NZ591728A (en) 2012-12-21
BRPI0921701B1 (pt) 2022-05-03
NL301067I1 (pt) 2020-10-13
FIC20200039I1 (fi) 2020-10-19
JP2014065732A (ja) 2014-04-17
ME02666B (me) 2017-06-20
HUE031802T2 (en) 2017-08-28
LTPA2020530I1 (lt) 2020-11-10
RS55365B1 (sr) 2017-03-31
KR101655961B1 (ko) 2016-09-08
CY2020034I1 (el) 2020-11-25
SMT201600397B (it) 2017-01-10
SI2960244T1 (sl) 2017-02-28
CN102203100B (zh) 2014-08-27
PE20120010A1 (es) 2012-02-07
UA105190C2 (ru) 2014-04-25
FR20C1050I2 (fr) 2021-10-15
CL2011000939A1 (es) 2011-09-16
TW201020259A (en) 2010-06-01
EA201170632A1 (ru) 2011-12-30
EA019520B1 (ru) 2014-04-30
JP5498393B2 (ja) 2014-05-21
CA2736953C (en) 2017-07-11
CY1118536T1 (el) 2017-07-12
WO2010050468A1 (ja) 2010-05-06
FR20C1050I1 (pt) 2020-11-27
CO6331443A2 (es) 2011-10-20
JPWO2010050468A1 (ja) 2012-03-29
MY155655A (en) 2015-11-13
AU2009310959B2 (en) 2015-05-07
US9238657B2 (en) 2016-01-19
EP2341053A4 (en) 2012-08-08
BRPI0921701A2 (pt) 2020-08-11
ES2564836T3 (es) 2016-03-29
AU2009310959A1 (en) 2010-05-06

Similar Documents

Publication Publication Date Title
BRPI0921701B8 (pt) Cefarosporina tendo um grupo catecol, seu uso e composição farmacêutica que a compreende
CL2014003181A1 (es) Compuestos derivados de benzamidas n- sustituidas o piridinamidas n-sustituidas; composicion farmaceutica que los comprende; metodo de tratamiento; y su uso para el tratamiento de enfermedades o trastornos seleccionados de dolor, depresion y enfermedades cardiovasculares, respiratorias o psiquiatricas o combinaciones de estas.
BRPI0809977A8 (pt) Uso de um composto, compostos e composição farmacêutica que o contém
EA200802058A1 (ru) Производные циклоалкиламинокислот и их фармацевтические композиции
EA200802390A1 (ru) Конъюгаты аналогов азиридилэпотилона и фармацевтические композиции, содержащие их
GT200800189A (es) Derivados de amida y su aplicación para el tratamiento de enfermedades relacionadas con proteína-g
MX2019004578A (es) Oxisteroles y metodos de uso de los mismos.
MY147390A (en) Substituted isoindoles as bace inhibitors and their use
BR112012033770A2 (pt) novo derivado de nicotinamida ou sal do mesmo
MY152535A (en) Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmaceutical compositions and novel use as met inhibitors
MX2010009752A (es) Compuestos de oxadiazoantraceno para el tratamiento de diabetes.
NO20083434L (no) Benzamid- og heteroarenderivater
ECSP055676A (es) Piperazinas heterocíclicas sustituidas para el tratamiento de la esquizofrenia
EA201190235A1 (ru) Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
GB0612423D0 (en) Therapeutic agents
NI201100050A (es) Derivados amida de heteroarilos su uso como activadores de glucoquinasa.
BR112013011580A2 (pt) derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep
AR074604A1 (es) Derivados de 5-amino-2-(1-hidroxi-etil)-tetrahidropirano.
AR074608A1 (es) Derivados de 2-(piperidin-1-il)-4-heterociclil-tiazol-5-carboxilico para infecciones bacterianas
TW200612936A (en) Indole derivatives
BRPI0507903A (pt) derivados de quinazolina e composição farmacêutica compreendendo os mesmos
EA201101621A1 (ru) Производные бензоксазолона в качестве ингибиторов альдостеронсинтазы
DE602004008959D1 (de) Benzoäbüä1,4üdioxepinderivate
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/10/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2678 DE 03/05/2022 QUANTO AO NUMERO DO WO COD. INID (87).

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2678 DE 03/05/2022 QUANTO A DATA DE PUBLICACAO DO PCT (INID 87).